01 Shift Toward Fully Automated Whole Blood Component ProcessingThe blood processing devices and consumables market analysis shows that blood centers are adopting automated systems that separate whole blood into red blood cells, plasma, and platelets through integrated processing cycles, replacing labor-intensive manual procedures. For instance, in October 2026, Terumo Blood and Cell Technologies reported that Versiti became the 10th U.S. blood center to adopt its Reveos automated blood processing system, supporting greater platelet production capacity.
02 Integration of Blood Processing Platforms with Digital Monitoring SoftwareManufacturers are integrating blood processing equipment with software platforms and blood processing devices and consumable systems that capture processing data, standardize workflows, and improve traceability across blood collection and component preparation. For example, Terumo BCT's Reveos system operates alongside its Lumia software platform, combining automated processing with digital workflow management at blood centers.
01 The blood processing devices and consumables market forecasts strategic investment activity driven by the expansion of automated blood collection systems, apheresis equipment, and advanced blood component separation technologies. In May 2026, Vitestro raised an oversubscribed Series B round of USD 60 million with participation from Labcorp Venture Fund, Mayo Clinic, Sutter Health, and existing investors. The funding will support the development of its Aletta autonomous robotic blood collection device, manufacturing scale-up, clinical expansion, and regulatory approval in the US, expanding blood processing devices and consumable applications.
01 Adoption of Pathogen Reduction Technologies Drives Blood Processing Devices and Consumable Products DemandAn emphasis on transfusion safety is encouraging blood centers to adopt pathogen reduction systems for platelet and plasma components. For example, the U.S. FDA-approved Cerus INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections, including sepsis, in platelet components. The FDA approved updated product labeling incorporating five-day platelet recovery and survival data, supporting its use in blood component processing.
02 Expansion of Closed System Blood Processing Boost Blood Processing Devices and Consumables Market GrowthThe need to minimize bacterial contamination during blood collection and component preparation is driving demand for closed-system processing bags, tubing sets, and sterile connection devices. The World Health Organization's Good Practices for Blood Establishments guideline strongly recommends closed systems for all stages of blood component processing, allowing open systems only in exceptional circumstances with additional contamination controls. This recommendation supports wider adoption of integrated, sterile processing consumable devices ac
03 Impact Analysis of Key Drivers in Blood Processing Devices and Consumables MarketDriversMarket ImpactAdoption of Pathogen Reduction TechnologiesAn emphasis on transfusion safety is driving blood centers to adopt pathogen reduction systems that minimize the risk of transfusion-transmitted infections in platelet and plasma processing.Expansion of Closed-System Blood ProcessingDemand for improved sterility and reduced contamination risks is encouraging blood banks to use closed-system processing equipment and sterile disposable consumables.Use of Automated Cell Processing for Advanced TherapiesDemand for improved sterility and reduced contamination risks is encouraging blood banks to use closed-system processing equipment and sterile disposable consumables.Development of Advanced Buffy-Coat Processing SystemsDemand for efficient separation of whole blood into components is encouraging the adoption of advanced buffy-coat processing systems that improve platelet and red blood cell preparation.Demand for Automated Blood Component SeparationIncreasing requirements for red blood cells, platelets, and plasma are driving blood centers to invest in automated separation equipment that improves processing efficiency, component yield, and workflow consistency.
01 Risk of Contamination During Processing Limits Market GrowthBlood processing involves multiple steps, including collection, separation, transfer, and storage, creating several points where contamination can occur. A breach in sterile connections, damaged collection bags, or improper handling can introduce bacteria into blood components, making them unsuitable for transfusion. This risk increases the need for sterile single-use consumables, validated processing equipment, and stringent quality checks, adding to operational costs.
02 Stringent Regulatory and Quality Requirements Restrain Blood Processing Devices and Consumables Industry GrowthBlood processing devices and consumables technology must meet strict requirements for sterility, biocompatibility, material safety, performance, and shelf life before they can be marketed. For example, the U.S. FDA's September 2026 guidance for buffy-coat blood processing systems specifies requirements for product design, manufacturing controls, biocompatibility testing, sterilization validation, and container integrity. These requirements increase product testing, validation, and regulatory submission costs, creating challenges for blood processing devices and consumable manufacturers, particularly smaller suppliers.
03 Impact Analysis of Key Restraints in Blood Processing Devices and Consumables MarketRestraintsMarket ImpactHigh Cost of Automated Blood Processing EquipmentSignificant upfront investment in automated separation, apheresis, and pathogen reduction systems limits adoption among smaller blood banks and healthcare facilities.Risk of Contamination During ProcessingBreaches in sterile handling, equipment integrity, or consumable quality can contaminate blood components, resulting in product wastage and transfusion safety risks.Stringent Regulatory and Quality RequirementsExtensive validation, quality-control procedures, and regulatory compliance requirements increase product development timelines and operating costs for manufacturers.Limited Shelf Life of Blood ComponentsShort storage periods for platelets and other blood components increase pressure on blood centers to maintain efficient processing, inventory management, and distribution systems.Dependence on Specialized ConsumablesRequirements for compatible single-use bags, tubing sets, filters, and collection kits increase recurring procurement costs and supplier dependence.
01 Expansion of Plasma Collection Infrastructure Open New Revenue AvenuesDemand for plasma-derived therapies, including immunoglobulins and albumin, is creating opportunities for specialized plasma collection centers and automated plasmapheresis equipment. For example, in March 2026, Kamada received FDA approval for its San Antonio plasma collection center in Texas, which has an annual collection capacity of approximately 50,000 liters and can collect both normal source and specialty plasma. This expansion creates demand for plasma collection machines, sterile collection kits, disposable tubing sets, and component separation systems used by plasma centers.
02 Development of Cord Blood Processing Systems Expands Market PotentialAn interest in cord blood banking and stem cell-based treatments is creating demand for automated systems that isolate and preserve viable stem cells from umbilical cord blood. In March 2026, the U.S. FDA approved the addition of the ThermoGenesis AXP II System for automated cord blood processing at the Carolinas Cord Blood Bank. This creates opportunities for blood processing devices and consumable suppliers of automated cell separation equipment, sterile processing kits, cryopreservation bags, and monitoring systems used by cord blood banks.
November 2026 Terumo Blood and Cell Technologies received China's National Medical Products Administration registration for its locally manufactured Trima Accel Automated Blood Collection System.
October 2026 Versiti became the tenth US blood center to adopt Terumo BCT's Reveos Automated Blood Processing System.
August 2026 Vitestro received US FDA De Novo authorization for Aletta, an autonomous robotic phlebotomy device.
June 2026 Grifols launched Evanzys IH, a modular automated system for processing immunohematology samples in transfusion medicine laboratories.
February 2026 Haemonetics received US FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology.